Open AccessImatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
Author(s) -
Pradeep Balasubramanian,
Soumya Jagadeesan,
Jacob Thomas
Publication year - 2015
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.164447
Subject(s) - myeloid leukemia , imatinib , hypopigmentation , hyperpigmentation , medicine , tyrosine kinase inhibitor , tyrosine kinase , nilotinib , imatinib mesylate , cancer research , leukemia , dermatology , cancer , receptor
Imatinib, a tyrosine kinase inhibitor, is well known to cause hypopigmentation because of its inhibitory effect on melanocytes. Herewith we report a case of chronic myeloid leukemia who developed extensive hyperpigmentation following imatinib therapy